Nello Mainolfi - 05 Jan 2026 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Chief Executive Officer, Director
Signature
/s/ Bruce Jacobs, as Attorney-in-Fact
Issuer symbol
KYMR
Transactions as of
05 Jan 2026
Net transactions value
+$99,994
Form type
4
Filing time
06 Jan 2026, 16:40:08 UTC
Previous filing
31 Dec 2025
Next filing
25 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mainolfi Nello Chief Executive Officer, Director C/O KYMERA THERAPEUTICS, INC., 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN /s/ Bruce Jacobs, as Attorney-in-Fact 06 Jan 2026 0001821189

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Options Exercise $99,994 +3,118 +0.47% $32.07 666,195 05 Jan 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -3,118 -0.69% $0.000000 446,882 05 Jan 2026 Common Stock 3,118 $32.07 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date.